Jennison Associates LLC Lowers Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Jennison Associates LLC trimmed its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 8.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 439,562 shares of the company’s stock after selling 38,259 shares during the period. Jennison Associates LLC owned approximately 0.89% of Prestige Consumer Healthcare worth $26,910,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PBH. Sequoia Financial Advisors LLC boosted its position in shares of Prestige Consumer Healthcare by 1.8% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 10,068 shares of the company’s stock worth $576,000 after purchasing an additional 179 shares in the last quarter. Pinnacle Associates Ltd. raised its stake in shares of Prestige Consumer Healthcare by 0.8% during the 3rd quarter. Pinnacle Associates Ltd. now owns 24,672 shares of the company’s stock worth $1,411,000 after buying an additional 200 shares during the last quarter. Pacer Advisors Inc. raised its stake in shares of Prestige Consumer Healthcare by 85.7% during the 4th quarter. Pacer Advisors Inc. now owns 442 shares of the company’s stock worth $27,000 after buying an additional 204 shares during the last quarter. Global Retirement Partners LLC raised its stake in Prestige Consumer Healthcare by 22.6% in the 3rd quarter. Global Retirement Partners LLC now owns 1,364 shares of the company’s stock valued at $78,000 after purchasing an additional 251 shares during the last quarter. Finally, Raymond James & Associates raised its stake in Prestige Consumer Healthcare by 0.4% in the 3rd quarter. Raymond James & Associates now owns 96,433 shares of the company’s stock valued at $5,515,000 after purchasing an additional 394 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Trading Down 1.5 %

PBH opened at $70.13 on Thursday. The firm has a 50 day moving average price of $70.88 and a 200 day moving average price of $64.08. Prestige Consumer Healthcare Inc. has a 1 year low of $55.96 and a 1 year high of $75.31. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.09 and a quick ratio of 1.92.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, February 8th. The company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.04 by $0.02. The firm had revenue of $282.74 million during the quarter, compared to the consensus estimate of $280.25 million. Prestige Consumer Healthcare had a negative net margin of 7.11% and a positive return on equity of 14.09%. The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.04 EPS. Analysts forecast that Prestige Consumer Healthcare Inc. will post 4.33 EPS for the current year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 5,336 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $69.00, for a total value of $368,184.00. Following the completion of the sale, the senior vice president now owns 15,934 shares of the company’s stock, valued at $1,099,446. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on PBH. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, February 10th. TheStreet upgraded Prestige Consumer Healthcare from a “c+” rating to a “b-” rating in a report on Monday, February 12th. One research analyst has rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare presently has an average rating of “Moderate Buy” and a consensus target price of $110.00.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.